The Perfect Storm of Catalysts Could Give Leaf Stocks a $9 Billion Boost this November 2020 

With FDA Approval Pending, Rapid Therapeutic Science Laboratories’ (STOCK:RTSL) Innovative New Product Could Make it THE Leaf Play of 2020

News Update 9-30-20:
Rapid Therapeutic Enters Letter of Intent to Expand Production Capability to 3,000,000 MDI and $100,000,000 in Revenue Annually

Rapid Therapeutic Science Laboratories (STOCK:RTSL) is racing to meet medical leaf demand, with its metered dose inhaler that delivers cannabinoids straight to the systemic blood system with 98% bioavailability.(1)

That alone is unlocking big opportunity.

Top 6 Reasons to Have Rapid Therapeutic Science (STOCK:RTSL)
on Your Radar Immediately


1) Rapid Therapeutic Science Laboratories (STOCK:RTSL) is well positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(2)

2) Its products deliver measured amounts of cannabinoids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.

3) Its Rxoid Metered Dose Inhaler is 98% bioavailable in mere seconds.

4) Compared to an edible, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the blood stream.

5) The 2020 election could change the very landscape of the U.S. leaf market, creating a potential $35.1 billion revenue opportunity by 2025, says New Frontier Data.(2)

6) State ballot measures in Arizona, Mississippi, Montana, New Jersey, and South Dakota could green light leaf and add up to $9 billion to the market.(2)

There’s a perfect storm of factors brewing expected to drive monumental demand for leaf…

Taking leaf inhaler stocks like Rapid Therapeutic Science (STOCK:RTSL) along for the ride.

For one, despite a delay in the U.S. House of Representatives to legally leaf nationally, five more states — Arizona, Mississippi, Montana, New Jersey, South Dakota – will vote to legalize its use this November 2020.(2)

A yes vote from each could easily change the very landscape of the market.

“The 2020 election could be one of the most consequential and historical events to change the landscape of the legal U.S industry,” New Frontier Data CEO Giadha DeCarcer said, as quoted by Yahoo Finance. “With $9 billion in new revenue from 2022-2025, should all five states ballot measures pass, New Frontier Data estimates that revenues from all legal U.S. markets will reach $35.1B in 2025.”(2)

Two, there’s plenty of pent-up demand for the legalization of leaf.

A Pew Research Center survey found that 67% of the U.S. supports leaf legalization.(3)

And, a Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016.  On top of that, 14% of Americans now use leaf products.(4)

Three, for those seeking relief from medical and mental health issues, there’s big demand for quick relief and higher levels of bioavailability.

All as Leaf Has Been Shown to Reduce Issues of Depression, Anxiety, and Stress

According to a study in the Journal of Affective Disorders, leaf can help reduce issues of depression, anxiety, and stress in the short-term.(5)

Plus, demand for medical leaf is accelerating because of reported health benefits, including:

• Reduction of arthritis pain
• Reduction of migraines, and other headache issues
• Reduction of inflammation
• Reduction of sore muscle discomfort
• Relief from epilepsy and seizures

Those Are Big Catalysts for Rapid Therapeutic Science Laboratories (STOCK: RTSL)

Rapid Therapeutic Science Laboratories is focused on manufacturing and marketing leaf aerosol delivery systems-based on pressurized Metered Dose Inhaler (MDI) technology referred to as Rxoid MDI – which delivers approximately 98% of each dose of leaf to the deep lung tissue for immediate transport to your brain via your systemic blood stream.

Only around 2% is lost during exhalation.

Compared to an edible, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the blood stream.(6)

“MDIs deliver Active Pharmaceutical Ingredients (API’s) into the blood stream within seconds of inhalation. RTSL’s MDIs are a safe and convenient replacement for vape pens, tanks, and mods, and deliver a 98% bioavailable dose of leaf,” says Sean Berrier, Sr. VP and Co-founder.(7)

Rapid Therapeutic Science Laboratories (STOCK:RTSL) Just Filed with the US FDA

Rapid Therapeutic Science Laboratories just engaged FDA Compliance Solutions, LLC to begin the initial FDA regulatory process of registering their new facilities and ultimately all products.

“We look forward to having our facilities and products fully registered. This will ensure our products adhere to the highest standards of safety and efficacy as required by the FDA for any type of medical product being sold in the US or abroad. Except for our cannabinoids, all our consumables and excipients are already listed in Drug Master Files (DMF) with the FDA. This is the first step in ultimately obtaining a fully compliant product in the anticipated regulatory environment related to cannabinoids,” said CEO Donal R. Schmidt Jr.(7)

Rapid Therapeutic Science Laboratories Already Seeing Record Amount of Orders

In June 2020, the company received an order for a 100,000 unit wholesale order of its Rxoid brand 5.0 mg proprietary leaf/CBG formulation which delivers approximately 98% bioavailable dose of leaf directly to the systemic blood stream.

By July 2020, Rapid Therapeutic Science Laboratories received an additional commitment of 150,000 units under a 100,000 unit wholesale order.

Rapid Therapeutic Science Laboratories Also Launched New Lifestyle Brand, “nhaler”

Rapid Therapeutic Science Laboratories also just announced a relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand, nhāler.

Better still, the company just announced its new ISO 13485 laboratory is ready to begin manufacturing the nhaler brand.

“Our new laboratory allows RTSL to produce up to 2.9 million nhāler and Rxoid™ MDI per year. In addition, as demand increases, we can scale it to double the output with minimal additional personnel or capital outlay in about 9-12 weeks. It also reduces our manufacturing expenses and is a key process to eventual FDA approval of our MDI product line. Certainly, as we produce other aerosolized products in the future such as prescription medication, we will need this lab. I want to congratulate our team for getting the build-out finished on time and under budget.”(9)

 

Top 6 Reasons to Have Rapid Therapeutic Science (STOCK:RTSL)
on Your Radar Immediately


1) Rapid Therapeutic Science Laboratories (STOCK:RTSL) is well positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(2)

2) Its products deliver measured amounts of cannabinoids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.

3) Its Rxoid Metered Dose Inhaler is 98% bioavailable in mere seconds.

4) Compared to an edible, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the blood stream.

5) The 2020 election could change the very landscape of the U.S. leaf market, creating a potential $35.1 billion revenue opportunity by 2025, says New Frontier Data.(2)

6) State ballot measures in Arizona, Mississippi, Montana, New Jersey, and South Dakota could green light leaf and add up to $9 billion to the market.(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 7/8/20 and ending on 10/2/20 to publicly disseminate information about (RTSL) via digital communications. We have been paid one hundred eighteen USD via bank wire transfer to disseminate information about (RTSL) via digital communications. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 10/5/20 and ending on 10/9/20 to publicly disseminate information about (RTSL) via digital communications. We have been paid an additional twenty thousand USD. We own zero shares of (RTSL) To date we have been paid one hundred sixty three thousand USD via bank wire transfer to disseminate information about (RTSL) via digital communications.

Disclaimer

Privacy Policy